Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Which of the following NSAIDs is used for Bartter syndrome?

Indomethacin. ### Explanation **Correct Answer: D. Indomethacin** **Mechanism and Rationale:** Bartter syndrome is a rare genetic renal tubular disorder characterized by defective salt reabsorption in the thick ascending limb of the loop of Henle. This leads to salt wasting, hypokalemia, metabolic alkalosis, and, crucially, **increased renal prostaglandin (PGE2) production**. Elevated PGE2 stimulates the renin-angiotensin-aldosterone system (RAAS), worsening the electrolyte imbalance. **Indomethacin** is the drug of choice because it is a potent non-selective COX inhibitor that effectively reduces renal prostaglandin synthesis. By inhibiting PGE2, Indomethacin helps decrease renin secretion, improves potassium levels, and mitigates polyuria and growth retardation in affected children. **Analysis of Incorrect Options:** * **A. Paracetamol:** It has weak peripheral anti-inflammatory and prostaglandin-inhibiting activity. It is ineffective in reducing the high renal prostaglandin levels seen in Bartter syndrome. * **B. Sulindac:** While an NSAID, it is a prodrug known for its "renal-sparing" effect (it inhibits systemic COX but has less effect on renal prostaglandins). This makes it unsuitable for a condition where renal prostaglandin inhibition is the primary goal. * **C. Mefenamic acid:** Primarily used for dysmenorrhea and mild-to-moderate pain; it lacks the clinical evidence and potency required for managing Bartter syndrome. **High-Yield Clinical Pearls for NEET-PG:** * **Indomethacin** is also the drug of choice for **Patent Ductus Arteriosus (PDA)** and **Ankylosing Spondylitis**. * **Side Effects:** Indomethacin is notorious for GI toxicity (peptic ulcers) and frontal headaches. * **Gitelman Syndrome:** Often confused with Bartter; it mimics thiazide diuretic use (hypocalciuria), whereas Bartter mimics loop diuretic use (hypercalciuria). Indomethacin is less central to Gitelman treatment than Bartter.

Q: Prolonged use of aspirin causes:

Hypoprothrombinemia. **Explanation:** **Why Hypoprothrombinemia is correct:** Prolonged use of high-dose aspirin (salicylates) can lead to **hypoprothrombinemia** (deficiency of Factor II). This occurs because salicylates interfere with the utilization of Vitamin K by the liver, similar to the mechanism of warfarin [2]. By inhibiting the synthesis of Vitamin K-dependent clotting factors (II, VII, IX, and X), aspirin prolongs the Prothrombin Time (PT) [2]. This effect is distinct from aspirin’s more common antiplatelet action, which involves the irreversible inhibition of COX-1 and thromboxane A2. **Why the other options are incorrect:** * **B. Hyperprothrombinemia:** This refers to an excess of prothrombin, which would increase clotting tendency. Aspirin acts as an anticoagulant/antiplatelet agent, making this physiologically opposite to its effect. * **C. Hypophosphatasia:** This is a rare genetic disorder characterized by low levels of alkaline phosphatase. Aspirin has no known clinical link to the inhibition of this enzyme. * **D. Hypercalcemia:** Aspirin does not significantly affect systemic calcium homeostasis [3]. Hypercalcemia is more commonly associated with thiazide diuretics or Vitamin D toxicity. **High-Yield Clinical Pearls for NEET-PG:** 1. **Dual Hemostatic Defect:** Aspirin causes bleeding via two mechanisms: **Platelet dysfunction** (low doses) and **Hypoprothrombinemia** (prolonged high doses) [2]. 2. **Reversibility:** Aspirin-induced hypoprothrombinemia can be reversed by administering **Vitamin K** [1]. 3. **Acid-Base Balance:** In salicylate poisoning, the classic pattern is **Respiratory Alkalosis** followed by **Metabolic Acidosis** (with a high anion gap). 4. **Reye’s Syndrome:** Avoid aspirin in children with viral infections (flu/chickenpox) due to the risk of fulminant hepatic failure and encephalopathy.

Q: Which of the following immunosuppressive agents acts selectively by inhibiting helper T-cells?

Cyclosporine. **Explanation:** The correct answer is **Cyclosporine**. **Mechanism of Action:** Cyclosporine is a **calcineurin inhibitor**. It acts selectively on T-helper (CD4+) cells. Under normal conditions, T-cell activation leads to an increase in intracellular calcium, which activates calcineurin. Calcineurin dephosphorylates the **Nuclear Factor of Activated T-cells (NFAT)**, allowing it to enter the nucleus and promote the transcription of **Interleukin-2 (IL-2)**. Cyclosporine binds to **cyclophilin**, and this complex inhibits calcineurin, thereby blocking IL-2 production and the subsequent proliferation of helper T-cells. **Why other options are incorrect:** * **Cyclophosphamide:** An alkylating agent that cross-links DNA. It is non-selective and affects both B-cells and T-cells, as well as other rapidly dividing cells. * **Azathioprine:** A purine antimetabolite (prodrug of 6-mercaptopurine) that inhibits DNA synthesis. It suppresses the proliferation of both T and B lymphocytes non-selectively. * **Cytosine arabinoside (Cytarabine):** A pyrimidine antagonist used primarily as a cytotoxic chemotherapy agent for leukemias; it is not used as a selective immunosuppressant for T-cells. **NEET-PG High-Yield Pearls:** * **Side Effects of Cyclosporine:** Nephrotoxicity (most common), Gingival Hyperplasia, Hirsutism, Hypertension, and Neurotoxicity (tremors). * **Monitoring:** Therapeutic Drug Monitoring (TDM) is essential due to its narrow therapeutic index. * **Comparison:** Unlike Cyclosporine, **Tacrolimus** binds to **FKBP-12** but shares the same mechanism of inhibiting calcineurin. Tacrolimus is more potent and does *not* cause gingival hyperplasia or hirsutism (it may cause alopecia instead).

Q: A 35-year-old woman has been taking acetylsalicylic acid (aspirin) for arthritis for several years. Her joint pain is reduced with this therapy, though the joint destruction with loss of articular cartilage still continues. The aspirin therapy temporarily alleviates her pain. This pain reduction is primarily the result of diminishing the inflammatory response characterized by:

Prostaglandin mediated vasodilation. **Explanation:** The primary mechanism of action of Aspirin (Acetylsalicylic acid) is the **irreversible inhibition of Cyclooxygenase (COX-1 and COX-2) enzymes**. This inhibition prevents the conversion of arachidonic acid into prostaglandins (PGs), specifically PGE2 and PGI2. **1. Why Option C is Correct:** In the inflammatory process, prostaglandins (especially PGE2) act as potent vasodilators and sensitize peripheral nociceptors to pain-producing mediators like bradykinin and histamine. By inhibiting PG synthesis, aspirin reduces **prostaglandin-mediated vasodilation**, edema, and the sensitization of pain receptors. This alleviates the "rubor" (redness), "calor" (heat), and "dolor" (pain) associated with inflammation. **2. Why Other Options are Incorrect:** * **Option A:** Aspirin does not inhibit the Lipoxygenase (LOX) pathway. In fact, by blocking the COX pathway, arachidonic acid may be shunted toward the LOX pathway, potentially increasing **Leukotriene B4** (a potent neutrophil chemotactic agent). * **Option B:** While aspirin is an antipyretic, the question asks specifically about the reduction of the **inflammatory response** in the joints. Fever is a systemic response, not the primary local inflammatory mechanism being treated in arthritis. * **Option D:** Aspirin does not prevent the **generation of bradykinin** (which is derived from the kinin system). It only prevents prostaglandins from *sensitizing* nerve endings to the effects of bradykinin. **High-Yield NEET-PG Pearls:** * **Disease Modification:** Aspirin and NSAIDs are **Symptomatic Treatments** only. They do not prevent joint destruction or disease progression in Rheumatoid Arthritis (unlike DMARDs). * **Zero-Order Kinetics:** At high anti-inflammatory doses, Aspirin follows zero-order elimination. * **Aspirin Triad (Samter’s):** Asthma, Nasal polyposis, and Aspirin sensitivity (due to leukotriene shift).

Q: Which of the following drugs is used in the treatment of acute gout?

Colchicine. **Explanation:** The management of gout is divided into two phases: treatment of acute attacks and long-term prophylaxis (urate-lowering therapy) [1, 2]. **1. Why Colchicine is Correct:** Colchicine is a first-line agent for **acute gout** [3]. Its primary mechanism involves binding to tubulin, inhibiting microtubule polymerization [2]. This disrupts the migration and phagocytic activity of neutrophils into the inflamed joint, thereby reducing the release of inflammatory mediators (like LTB4) and lactic acid [1, 2]. By inhibiting the "inflammasome" complex, it effectively halts the acute inflammatory cascade [2]. **2. Why the Other Options are Incorrect:** * **Allopurinol (Option A):** This is a Xanthine Oxidase inhibitor used for **chronic prophylaxis** [3]. It should **never** be started during an acute attack because a rapid drop in serum uric acid can cause the mobilization of urate crystals from tissues, potentially worsening or prolonging the acute episode [3]. * **Pamidronate (Option C):** This is a Bisphosphonate used to treat osteoporosis, Paget’s disease, and hypercalcemia of malignancy. It has no role in gout management. * **Methotrexate (Option D):** This is a DMARD (Disease-Modifying Anti-Rheumatic Drug) used primarily for Rheumatoid Arthritis and psoriasis. It is not used for gout. **High-Yield Clinical Pearls for NEET-PG:** * **First-line for Acute Gout:** NSAIDs (e.g., Indomethacin, Naproxen) are generally preferred over colchicine due to better tolerability [3]. * **Colchicine Toxicity:** The dose-limiting side effect is **diarrhea** [4]. * **Uricosuric Drugs:** Probenecid and Lesinurad increase uric acid excretion but are contraindicated in patients with renal stones [1]. * **Febuxostat:** A non-purine selective inhibitor of xanthine oxidase, used if Allopurinol is not tolerated.

Q: Which drug commonly causes analgesic nephropathy?

Phenacetin. **Explanation:** **Analgesic Nephropathy** is a form of chronic tubulointerstitial nephritis and renal papillary necrosis caused by the long-term, excessive consumption of analgesic mixtures. **Why Phenacetin is the Correct Answer:** Phenacetin is historically the drug most strongly associated with analgesic nephropathy. It was frequently used in combination with aspirin and caffeine (APC tablets). Phenacetin acts as a cumulative toxin; its metabolite, **p-phenetidine**, causes oxidative damage to the renal papillae. Due to its high nephrotoxic potential and association with transitional cell carcinoma of the renal pelvis, phenacetin has been withdrawn from the market in most countries. **Analysis of Incorrect Options:** * **A. Aspirin:** While aspirin inhibits prostaglandins (which maintain renal blood flow), it rarely causes classic analgesic nephropathy when used alone. However, it synergistically increases the toxicity of phenacetin in combination products. * **B. Ibuprofen:** As a standard NSAID, ibuprofen can cause acute kidney injury (AKI) or chronic interstitial nephritis, but it is not the "classic" historical cause of the specific syndrome known as analgesic nephropathy. * **C. Phenylbutazone:** This is a potent NSAID primarily associated with severe hematological side effects like **aplastic anemia** and agranulocytosis, rather than being the primary driver of analgesic nephropathy. **High-Yield Clinical Pearls for NEET-PG:** * **Pathognomonic Feature:** Renal Papillary Necrosis (often visualized as the "Ring Sign" on IVP). * **Classic Presentation:** A middle-aged patient with chronic pain (e.g., headache/backache) presenting with sterile pyuria, anemia, and shrunken kidneys. * **Malignancy Risk:** Long-term phenacetin use is a significant risk factor for **urothelial (transitional cell) carcinoma** of the renal pelvis and bladder.

Q: Which of the following is a disease-modifying antirheumatic drug (DMARD) commonly used in rheumatoid arthritis?

Methotrexate. **Explanation:** **Methotrexate (MTX)** is considered the **"Anchor Drug"** and the first-line Disease-Modifying Antirheumatic Drug (DMARD) for Rheumatoid Arthritis (RA). Its primary mechanism in RA is the inhibition of **aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase**, leading to increased extracellular adenosine, which exerts potent anti-inflammatory effects. At higher doses (used in oncology), it inhibits dihydrofolate reductase (DHFR). It is preferred due to its efficacy, favorable cost-profile, and ability to reduce radiologic progression of the disease. **Analysis of Options:** * **A. Azathioprine:** While it has DMARD properties, it is generally reserved for refractory cases or systemic involvement (like vasculitis) due to its toxicity profile. It is not a first-line conventional synthetic DMARD (csDMARD). * **B. Hydroxychloroquine:** This is a "mild" DMARD. It is often used in very early/mild RA or as part of "Triple Therapy" (MTX + Sulfasalazine + HCQ), but it is rarely used as monotherapy for aggressive disease because it does not reliably prevent bone erosions. * **D. Leflunomide:** This is an effective DMARD that inhibits **dihydroorotate dehydrogenase**, arresting pyrimidine synthesis. While it is a valid alternative to Methotrexate, MTX remains the gold standard and the most "commonly used" initial therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Supplementation:** Always co-prescribe **Folic acid** (5 mg/week) to reduce MTX side effects like mucosal ulcers and GI upset. * **Monitoring:** Monitor Liver Function Tests (LFTs) due to the risk of hepatic fibrosis and CBC for myelosuppression. * **Contraindications:** MTX is strictly **contraindicated in pregnancy** (Teratogenic). * **Fast Fact:** MTX is usually administered as a **once-weekly dose**, not daily.

Q: Short-acting synthetic opioid is

Remifentanil. **Explanation:** The correct answer is **Remifentanil**. The primary medical concept here is the **metabolism and duration of action** of synthetic opioids. Remifentanil is unique among opioids because it contains an **ester linkage**. This allows it to be rapidly metabolized by **non-specific plasma and tissue esterases**, rather than relying on hepatic metabolism. Consequently, it has an ultra-short half-life (approximately 3–10 minutes) and a predictable, rapid recovery profile that is independent of the duration of infusion (context-sensitive half-life). **Analysis of Options:** * **Remifentanil (Correct):** The shortest-acting opioid due to rapid esterase hydrolysis. It is ideal for procedures requiring intense analgesia with immediate recovery. * **Fentanyl:** A potent synthetic opioid, but it is highly lipid-soluble and undergoes hepatic metabolism. It has a longer duration of action compared to remifentanil. * **Alfentanil:** While it has a faster *onset* than fentanyl due to its low pKa (more unionized drug), its duration of action is longer than remifentanil. * **Sufentanil:** The most potent of the group (5–10x more than fentanyl), but it has a longer duration of action and a tendency for accumulation in fatty tissues. **High-Yield Clinical Pearls for NEET-PG:** * **Context-Sensitive Half-Life:** Remifentanil has the shortest context-sensitive half-life, making it the drug of choice for Total Intravenous Anesthesia (TIVA). * **Metabolism:** Remifentanil is the only opioid not significantly affected by hepatic or renal failure. * **Potency Order:** Sufentanil > Remifentanil > Fentanyl > Alfentanil > Morphine. * **Side Effect:** Rapid administration of these synthetic opioids can cause **Chest Wall Rigidity** (Wooden Chest Syndrome), which may require muscle relaxants for management.

Q: A 74-year-old man reports having multiple gout attacks of his left big toe. He is symptom-free currently and is prescribed allopurinol for gout prophylaxis. Which of the following is the most likely mechanism of action for this medication?

Inhibiting xanthine oxidase. **Explanation:** **Mechanism of Action (Correct Answer: C)** Allopurinol is a purine analog that acts as a competitive inhibitor of **Xanthine Oxidase (XO)**. Under normal physiological conditions, XO catalyzes the oxidation of hypoxanthine to xanthine and xanthine to **uric acid**. By inhibiting this enzyme, allopurinol reduces the plasma concentration and urinary excretion of uric acid, thereby preventing the formation of urate crystals in joints and tissues. **Analysis of Incorrect Options:** * **Option A:** This is counter-therapeutic; the goal of gout management is to decrease, not increase, uric acid levels. * **Option B:** This describes **Uricosurics** (e.g., Probenecid, Lesinurad), which inhibit the URAT1 transporter in the proximal tubule to increase excretion. Allopurinol actually decreases the total urate load. * **Option C:** This describes the mechanism of **Colchicine** (inhibits microtubule polymerization) or **NSAIDs** (COX inhibition), which are used for acute attacks. Allopurinol has no anti-inflammatory or analgesic activity and can actually precipitate an acute attack if started without prophylaxis. **High-Yield NEET-PG Pearls:** * **Active Metabolite:** Allopurinol is metabolized by XO into **Alloxanthine (Oxypurinol)**, which is a long-acting, non-competitive inhibitor of the same enzyme. * **Drug Interactions:** Since XO metabolizes **6-Mercaptopurine (6-MP)** and **Azathioprine**, co-administration with Allopurinol leads to toxic levels of these immunosuppressants. Doses must be reduced by 50-75%. * **HLA-B*5801:** Testing is recommended in certain populations (e.g., Han Chinese, Thai) to prevent **Stevens-Johnson Syndrome (SJS)**. * **Febuxostat:** A newer, non-purine selective inhibitor of XO used if allopurinol is not tolerated.

Q: Which antirheumatoid drug specifically acts on T-cells?

Abatacept. ### Explanation **Correct Answer: D. Abatacept** **Mechanism of Action:** Abatacept is a fusion protein (CTLA-4 linked to the Fc portion of IgG1) that acts as a **selective co-stimulation modulator**. For a T-cell to become fully activated, it requires two signals from an Antigen-Presenting Cell (APC). The second signal involves the binding of **CD80/86** on the APC to **CD28** on the T-cell. Abatacept binds to CD80/86 with high affinity, preventing it from interacting with CD28. This inhibits T-cell activation and the subsequent inflammatory cascade in Rheumatoid Arthritis. **Analysis of Incorrect Options:** * **A. Etanercept:** This is a soluble decoy receptor that binds to **TNF-α** and TNF-β, preventing them from interacting with cell surface receptors. It does not target T-cells directly. * **B. Infliximab:** This is a chimeric monoclonal antibody that binds directly to **TNF-α**. Like Etanercept, it is a TNF inhibitor, not a T-cell modulator. * **C. Rituximab:** This is a chimeric monoclonal antibody directed against the **CD20** antigen found on the surface of **B-lymphocytes**, leading to B-cell depletion. **High-Yield Clinical Pearls for NEET-PG:** * **Abatacept Mnemonic:** **A**batacept **A**nagonizes **A**PC-T cell interaction. * **Leflunomide:** Another T-cell related drug; it inhibits **dihydroorotate dehydrogenase**, leading to decreased pyrimidine synthesis and decreased T-cell proliferation. * **Anakinra:** An IL-1 receptor antagonist used in RA. * **Tocilizumab:** An IL-6 receptor antagonist. * **Screening:** Always screen for latent Tuberculosis (via Mantoux or IGRA) before starting any biological DMARD.

Question 1

Which of the following NSAIDs is used for Bartter syndrome?

Accepted Answer

Indomethacin

Answer

Paracetamol

Answer

Sulindac

Answer

Mefenamic acid

Question 2

Prolonged use of aspirin causes:

Accepted Answer

Hypoprothrombinemia

Answer

Hyperprothrombinemia

Answer

Hypophosphatasia

Answer

Hypercalcemia

Question 3

Which of the following immunosuppressive agents acts selectively by inhibiting helper T-cells?

Accepted Answer

Cyclosporine

Answer

Cyclophosphamide

Answer

Azathioprine

Answer

Cytosine arabinoside

Question 4

A 35-year-old woman has been taking acetylsalicylic acid (aspirin) for arthritis for several years. Her joint pain is reduced with this therapy, though the joint destruction with loss of articular cartilage still continues. The aspirin therapy temporarily alleviates her pain. This pain reduction is primarily the result of diminishing the inflammatory response characterized by:

Accepted Answer

Prostaglandin mediated vasodilation

Answer

Neutrophil chemotaxis by leukotriene B4

Answer

Fever resulting from interleukin-1 release

Answer

Pain resulting from bradykinin generation

Question 5

Which of the following drugs is used in the treatment of acute gout?

Accepted Answer

Colchicine

Answer

Allopurinol

Answer

Pamidronate

Answer

Methotrexate

Question 6

Which drug commonly causes analgesic nephropathy?

Accepted Answer

Phenacetin

Answer

Aspirin

Answer

Ibuprofen

Answer

Phenylbutazone

Question 7

Which of the following is a disease-modifying antirheumatic drug (DMARD) commonly used in rheumatoid arthritis?

Accepted Answer

Methotrexate

Answer

Azathioprine

Answer

Hydroxychloroquine

Answer

Leflunomide

Question 8

Short-acting synthetic opioid is

Accepted Answer

Remifentanil

Answer

Fentanyl

Answer

Alfentanil

Answer

Sufentanil

Question 9

A 74-year-old man reports having multiple gout attacks of his left big toe. He is symptom-free currently and is prescribed allopurinol for gout prophylaxis. Which of the following is the most likely mechanism of action for this medication?

Accepted Answer

Inhibiting xanthine oxidase

Answer

Increasing uric acid production

Answer

Blocking excretion of uric acid by renal tubular mechanism

Answer

Diminishing inflammation of acute gouty arthritis

Question 10

Which antirheumatoid drug specifically acts on T-cells?

Accepted Answer

Abatacept

Answer

Etanercept

Answer

Infliximab

Answer

Rituximab

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?